Reference : Les anticorps monoclonaux en neurologie.
Scientific journals : Article
Human health sciences : Neurology
Les anticorps monoclonaux en neurologie.
[en] Monoclonal antibodies in neurology
Jedidi, Zayd [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Jedidi, Haroun mailto [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Moonen, Gustave [Centre Hospitalier Universitaire de Liège - CHU > > Neurologie Sart Tilman >]
Belachew, Shibeshih mailto [Université de Liège - ULg > Département des sciences cliniques > Neurologie >]
Revue Médicale de Liège
Hopital de Baviere
Yes (verified by ORBi)
[en] Antibodies, Monoclonal/therapeutic use ; Antibodies, Neoplasm/therapeutic use ; Humans ; Immunoglobulin G/therapeutic use ; Nervous System Diseases/drug therapy ; Neuroprotective Agents/therapeutic use ; Receptors, Tumor Necrosis Factor/therapeutic use
[en] Since their inception in the 1970's, monoclonal antibody therapies became increasingly efficient and common in numerous medical conditions and their use in neurology has been boosted during the last couple of years with the rise of natalizumab (Tysabri). Furthermore, if most monoclonal antibodies currently assessed in neurologic conditions remain considered as experimental, they may soon become first-line approved treatments in a broad range of neuromuscular and demyelinating diseases. Since the introduction of new therapies is likely to unravel specific adverse events and sui generis iatrogenic disorders, it is important to be able to recognize the side-effects of monoclonal antibodies delivered for neurological or non-neurological diseases.

File(s) associated to this reference

Fulltext file(s):

Open access
JEDIDI RMLg 2009.pdfPublisher postprint233.48 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.